Save the date -BIA/MHRA Conference
The BioIndustry Association (BIA) and Medicines and Healthcare products Regulatory Agency (MHRA) are delighted to announce that the sixth joint regulatory conference on Accelerated Development and Access to Innovative Medicines for Patients will take place on Wednesday 4 May 2016 at the Royal Society of Medicine, London. This must-attend one-day conference will be the ideal place to hear the very latest thinking from senior experts and leading speakers from the MHRA, the European Medicines Agency (EMA), the life science industry, the NHS, NICE, academia and patient organisations including:
- Sir Hugh Taylor, Independent Chair, Accelerated Access Review (invited)
- Professor Sir John Bell, Chair, Accelerated Access Review's Expert Advisory Group
- Robert Hemmings, Manager, Licensing Division, MHRA, and Chair, CHMP’s Scientific Advice Working Party, EMA
- Dr Daniel O’Connor, Expert Medical Assessor, Licensing Division, MHRA
- Alan Morrison, Chairman, BIA Regulatory Affairs Advisory Committee
- Kate Beaujeux, Regulatory Affairs Senior Regional Director – Oncology, AstraZeneca
- Joanna Maitland Smith, Executive Director Regulatory Affairs, MSD
- Chris Walker, Executive Director, European Head of Regulatory Affairs (Non-Oncology), Amgen
The conference programme addresses some hot topics and developments to support innovation and optimise pathways and timely access to new medicines including:
- Accelerated access review in the UK
- UK Early Access to Medicines Scheme: two years on
- EU early access tools
- Adaptive pathways
- The new EMA’s PRIME (Priority Medicines) scheme
- What are the benefits of accelerated assessment in the EU?
See the conference website for an update from 2015 and view the post conference report.
Save the date in your diary today - registration opens in January
|
Venue
Royal Society of Medicine One Wimpole Street London W1G 0AE
Date
Wednesday 4 May 2016
Time
9.00 - 17.30
Who should attend?
The conference is aimed at professionals from
• Life sciences industry • Regulatory agencies • Academic institutions • Medical research charities • NHS clinical trial units • Contract research organisations • Biopharmaceutical manufacturers • Service providers
|